2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2814 Long-term outcomes of venetoclax in combination with 3+7 versus traditional 3+7 regimen for newly diagnosed acute myeloid leukemia: A real-world, single-center retrospective study

Yiping Wang, Xuemin Gao, MD2, Jun Feng3, Kaini Shen4, Jian Li, MD5
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijin, China, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background

Standard 3+7 intensive chemotherapy remains the backbone induction for fit patients with newly diagnosed acute myeloid leukemia (AML). Although prospective clinical trials show improved remission and survival by adding venetoclax to intensive regimens, real-world evidence remains scarce due to heterogeneity in treatment schedules. Here, we conducted a single-center retrospective study to evaluate the real-world effectiveness of venetoclax combined with intensive chemotherapy.

Methods

We retrospectively enrolled newly diagnosed AML patients who received anthracycline-based induction regimens with or without venetoclax between January 2016 and June 2025. The DA/IA cohort was treated from 2016 to 2024, whereas the DAV cohort was enrolled from 2022 to 2025 following institutional venetoclax availability. The DA/IA regimen comprised intravenous daunorubicin (60 mg/m2) or idarubicin (10-12 mg/m2) on Days 1-3, plus subcutaneous cytarabine (100 mg/m2 q12h) on Days 1-7. The DAV group received the DA backbone supplemented with oral venetoclax (ramped from 100 mg on Day 1 to 200 mg on Day 2, and 400 mg daily on Days 3-14). Most patients received 1-4 consolidation cycles with high-dose cytarabine intravenously (3 g/m2 q12h on Days 1-3); DAV patients received additional oral venetoclax (400 mg daily on Days 1-7) during consolidation. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was overall survival (OS), estimated by the Kaplan–Meier method and multivariable Cox regression. To rigorously adjust for immortal time bias, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was incorporated as a time-dependent covariate.

Results

Of 334 patients included (median age 50 years, IQR 38–59), 175 patients (52.4%) were male. Two hundred and thirty-eight patients received DA/IA and 96 received DAV. Common baseline mutations included NRAS (19.2%), NPM1 (17.7%), CEBPA (17.1%), DNMT3A (12.6%), and FLT3-ITD (12.0%). Baseline characteristics were generally balanced between the two cohorts. According to the ELN 2022 risk stratification, patients in the DA/IA and DAV groups were classified as favorable (45.6% vs. 44.2%), intermediate (26.2% vs. 30.5%), and adverse (28.3% vs. 25.3%). No significant intergroup difference was observed (P = 0.697). The DAV cohort achieved a significantly higher complete remission (CR) rate than DA/IA (93.5% vs. 74.2%, P = 0.001). Over a median follow-up of 38.9 months, 128 deaths (38.3%) occurred and 28 patients (8.4%) were lost to follow-up. Median PFS was not reached with DAV versus 10.1 months with DA/IA (P < 0.001), yielding 3-year PFS rates of 64.9% vs. 38.7%. The 3-year OS rate was superior with DAV (66.6% vs. 55.4%, P = 0.006), though median OS was not reached in either cohort. In univariate analysis, DAV regimen was associated with improved PFS (HR 0.35, P < 0.001) and OS (HR 0.54, P = 0.007). After adjustment for baseline characteristics and inclusion of allo-HSCT as a time-dependent covariate, DAV remained an independent protective factor for PFS (adjusted HR 0.28, P = 0.004), whereas its OS advantage lost statistical significance. Subgroup analyses confirmed consistent PFS benefit with DAV across all ELN 2022 risk groups. Secondary AML, extramedullary involvement, and intermediate/adverse ELN risk independently predicted worse PFS, whereas allo-HSCT was independently protective (HR 0.36, P = 0.005).

Conclusion

Adding venetoclax to standard 3+7 chemotherapy represents a promising frontline induction strategy that significantly improves PFS in fit AML patients across all ELN 2022 risk categories. By maximizing early anti-leukemic efficacy, the DAV regimen demonstrates strong potential to optimize frontline induction and facilitate a seamless transition to curative allo-HSCT in real-world practice.

Yiping Wang: No relevant conflicts of interest to declare.